Welcome to our dedicated page for Annovis Bio SEC filings (Ticker: ANVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Annovis Bio, Inc. (ANVS) SEC filings page provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. Annovis is a late-stage clinical drug platform company focused on neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease, and its filings offer detailed insight into its clinical programs, financial condition, capital structure, and governance.
Through periodic reports and current reports on Form 8‑K, Annovis discloses material events such as registered direct offerings of common stock and pre‑funded warrants under its Form S‑3 shelf registration statement, the intended use of proceeds for the continued clinical development of buntanetap and general corporate purposes, and engagement terms with placement agents. Other 8‑K filings describe leadership changes, including appointments and resignations in finance roles, annual meeting voting results, and matters such as NYSE listing compliance plan acceptance.
Investors following Annovis’ late-stage clinical activities can also use SEC filings to connect financial updates with the company’s development plans. Earnings-related 8‑K filings furnish press releases that summarize research and development expenses, general and administrative costs, and net loss figures for specified reporting periods, alongside narrative corporate updates on the pivotal Phase 3 Alzheimer’s trial and other clinical milestones.
On this page, users can review real-time updates as new filings appear on EDGAR, including future annual reports on Form 10‑K, quarterly reports on Form 10‑Q, and additional 8‑K disclosures. AI-powered tools on the platform can help summarize lengthy documents, highlight key sections on topics such as financing terms, clinical development priorities, or listing status, and make it easier to navigate complex language. For those analyzing ANVS, this filings archive is a primary source for understanding how Annovis reports its progress, risks, and obligations in connection with the development of buntanetap and its broader corporate activities.
Annovis Bio, Inc. is raising approximately $10 million through an underwritten registered direct offering of 5,263,156 shares of common stock and accompanying warrants to buy 5,263,156 additional shares. Each share-and-warrant combination is priced at $1.90, and the warrants have an exercise price of $2.50 per share, becoming exercisable six months after issuance and expiring about five and a half years later.
The company expects the offering to close on or about April 10, 2026, subject to customary conditions, with Canaccord Genuity acting as underwriter and sole bookrunner. Annovis plans to use the net proceeds primarily to continue Phase 3 clinical development of its lead drug candidate buntanetap for Alzheimer’s disease, as well as for working capital and general corporate purposes.
Annovis Bio, Inc. is conducting a registered direct offering of 5,263,156 shares of common stock paired with warrants to purchase up to 5,263,156 additional shares. Each share is sold together with a warrant at a combined public offering price of $1.90 per pair.
The warrants will be first exercisable six months after issuance, expire five and one-half years from issuance, and have an exercise price of $2.50 per share. The company expects net proceeds of approximately $9.175 million, which it plans to use to continue Phase 3 development of buntanetap for Alzheimer’s disease and for working capital and general corporate purposes. Shares outstanding were 29,269,237 as of April 8, 2026, and the expected post-offering outstanding share count is 34,532,393 assuming full sale of this offering.
Annovis Bio director Michael B. Hoffman made a large open-market purchase of the company’s common stock. On April 2, 2026, he bought 713,800 shares at $2.10 per share, increasing his direct holdings to 3,288,539 shares.
He also has indirect ownership of 223,357 shares held by The 2024 Hoffman Family Trust, over which he has both voting and investment power. The filing shows no derivative securities remaining, so this activity reflects a direct cash investment rather than an options exercise.
Annovis Bio, Inc. reported that effective March 23, 2026, Chief Financial Officer Mark Guerin is no longer employed by the company. The company stated that his departure did not arise from any disagreement regarding operations, policies, or practices.
The board of directors is expected to appoint Chief Executive Officer Maria Maccecchini to serve as Acting Chief Financial Officer until a permanent replacement is identified, temporarily combining the CEO and CFO responsibilities.
Annovis Bio, Inc. reported full-year 2025 results while advancing its lead drug buntanetap into later-stage trials. The company initiated a pivotal Phase 3 study in early Alzheimer’s disease and started an open-label extension study in Parkinson’s disease, highlighting biomarker data that suggest a potential disease-modifying effect.
For the year ended December 31, 2025, research and development expenses were $25.2 million versus $20.0 million in 2024, while general and administrative expenses were $4.5 million versus $6.7 million. Total operating expenses reached $29.7 million, leading to a net loss of $28.9 million compared with $24.6 million a year earlier. Basic net loss per share was $1.40 versus $2.02.
Cash and cash equivalents were $19.5 million as of December 31, 2025, up from $10.6 million at year-end 2024. Total stockholders’ equity increased to $16.9 million from $9.3 million, reflecting capital raised to support the expanded clinical program.
Annovis Bio files its annual report describing major progress in its neurodegeneration pipeline centered on lead drug buntanetap. The company is running a pivotal Phase 3 trial in early Alzheimer’s disease, designed with a 6‑month symptomatic readout and 18‑month disease‑modifying component, and an open‑label extension in Parkinson’s disease.
Prior Phase 2/3 AD and Phase 3 PD trials showed statistically significant cognitive and functional benefits in defined subgroups, and the FDA has aligned on a dual NDA path for short‑ and long‑term efficacy in AD. Annovis also highlights earlier‑stage assets ANVS405 for acute brain injury, ANVS301 for later‑stage dementia, and a broad patent estate expected to run into the 2040s.
Annovis Bio reported that an independent Data and Safety Monitoring Board completed a planned 6‑month safety review of its pivotal Phase 3 Alzheimer’s disease trial of buntanetap and recommended the study continue without changes. The DSMB found no safety concerns, and 6‑month safety data in Alzheimer’s patients were consistent with those previously observed in Parkinson’s patients.
The Phase 3 Alzheimer’s trial is recruiting across the United States and is about 40% complete. The first symptomatic efficacy results are expected in early 2027, followed by a disease‑modifying readout in early 2028. The company also noted that, given the aligned safety outcomes across Alzheimer’s and Parkinson’s studies, the FDA indicated it may consider accepting combined safety data in a future NDA submission.
Annovis Bio, Inc. filed a current report describing a planned investor communication. On January 28, 2026, the company will conduct a webinar to present information about its business or programs. The slide presentation for this webinar is being made available as Exhibit 99 and is incorporated by reference into the report.
The filing does not describe the webinar content in detail but makes clear that interested parties can review the full presentation materials through the attached exhibit.
Annovis Bio, Inc. director reported open-market purchases of the company’s common stock. On 12/08/2025, the reporting person bought 30,000 shares at $4.3398 per share and an additional 15,000 shares at $4.24 per share. After these transactions, the reporting person beneficially owned 2,574,739 shares of Annovis Bio common stock directly. An additional 223,357 shares are held indirectly through The 2018 Jane and Michael Hoffman Descendants Trust, over which the reporting person has voting and investment power.